Clinical Trial Update: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the combination of onalespib with dabrafenib and trametinib in patients with BRAF-mutant melanoma or metastatic/unresectable solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Solid Tumor
• Unresectable Solid Tumor

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Onalespib (onalespib)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Status: TERMINATED | Results posted: 2024-10-16